Quick answer: DSHEA peptide supplements are legal only when the peptide fits the 1994 law’s definition of a dietary ingredient, is taken by mouth, and is not excluded as a drug. Collagen peptides sold as powders or capsules generally fit. Synthetic research peptides such as BPC-157 do not: the Department of Defense’s supplement safety program states BPC-157 “is not a dietary ingredient” and is an unapproved drug,[6] and any injectable product falls outside the supplement definition entirely.[2]
Here is what the Dietary Supplement Health and Education Act (DSHEA) says, how its drug-exclusion clause works, and where peptides fit. For the wider regulatory picture, see our FDA and regulation hub.
What DSHEA is
DSHEA, Public Law 103-417, was signed on October 25, 1994. It amended the Federal Food, Drug, and Cosmetic Act to create a legal category for dietary supplements, treated as a type of food rather than a drug.[1]
The definition now sits at 21 U.S.C. 321(ff) (FD&C Act section 201(ff)). A dietary supplement is a product intended to supplement the diet that contains one or more dietary ingredients:[2]
- (A) a vitamin
- (B) a mineral
- (C) an herb or other botanical
- (D) an amino acid
- (E) a dietary substance for use by man to supplement the diet by increasing total dietary intake
- (F) a concentrate, metabolite, constituent, extract or combination of the above
The product must also be intended for ingestion in a form such as a tablet, capsule, powder, softgel or liquid, must not be represented as a conventional food or the sole item of a meal, and must be labeled as a dietary supplement.[2]
FDA does not approve supplements before they are sold. Companies are responsible for safety and truthful labeling, and FDA acts after products are on the market.[5]
Where peptides fit in the definition
Peptides are chains of amino acids, but category (D) covers amino acids, not every chain built from them. A peptide has to fit somewhere:
| Peptide | Likely category | Supplement status |
|---|---|---|
| Collagen peptides, whey or milk protein hydrolysates (oral) | (E) dietary substance with a long food history | Generally sold as supplements |
| Glutathione (oral) | (E) or (F), found in food | Sold as a supplement; injectable forms are drugs |
| BPC-157 | No clear category; synthetic | Not a dietary ingredient, per DoD’s Operation Supplement Safety[6] |
| Semaglutide, tirzepatide | Approved drugs | Excluded by 201(ff)(3)(B) |
| Any injectable or nasal peptide | Not for ingestion | Cannot be a supplement |
FDA has long read category (E) narrowly. In its 2016 revised draft guidance on new dietary ingredients, FDA maintained that a “dietary substance” means a substance commonly used as human food or drink, which excludes many novel synthetic compounds.[9] That guidance is a non-binding draft, but it shows the agency’s view.
The drug-exclusion clause, 21 USC 321(ff)(3)(B)
DSHEA includes a “race to market” rule. Under section 201(ff)(3)(B), a dietary supplement may not include:[2]
- an article approved as a new drug or licensed as a biologic, or
- an article authorized for investigation as a new drug or biologic for which substantial clinical investigations have been started and made public,
unless that article was marketed as a dietary supplement or food before the approval or authorization. FDA can create an exception by regulation, after notice and comment.
This clause is why approved peptide drugs such as semaglutide can never appear in a lawful supplement. It also means that once a company opens an IND and publicly runs substantial trials on a peptide, later supplement marketing can be blocked. Our guide to peptide clinical trial regulation explains the IND process.
The clause has been contested. In 2022 FDA concluded that NMN was excluded from supplements because it had been studied as a drug. After a citizen petition and a lawsuit by industry groups, FDA reversed course in letters dated September 29, 2025, concluding that NMN is not excluded. The analysis turned on whether the ingredient had been marketed as a supplement first.[8]
New dietary ingredients (NDIs)
A new dietary ingredient is one not marketed in the U.S. before October 15, 1994. Unless the ingredient has been present in the food supply as an article used for food in a form not chemically altered, the maker must notify FDA at least 75 days before marketing. The notification must explain why the supplement will reasonably be expected to be safe.[3][4]
An NDI notification is not an approval. FDA can respond with objections, and selling a supplement with an NDI that should have been notified but wasn’t makes it adulterated under the law. Synthetic peptides first made after 1994 would need a valid NDI notification even if they otherwise qualified as dietary ingredients, which most do not.
Why BPC-157 and similar peptides can’t be supplements
Several barriers stack up:
- Not a dietary ingredient. BPC-157 is a synthetic 15-amino-acid peptide, not a vitamin, mineral, botanical or amino acid, and it lacks a history as food. The Department of Defense’s Operation Supplement Safety states it is not a dietary ingredient and that it cannot be legally prescribed or sold over the counter. BPC-157 is also on WADA’s prohibited list (class S0) and the DoD prohibited ingredient list.[6]
- Route of use. Most BPC-157, TB-500, ipamorelin and similar products are sold for injection or nasal use. Neither is ingestion.[2]
- Intended use. Products promoted to heal injuries or treat disease are drugs under 21 U.S.C. 321(g), whatever their label says.[2]
- FDA’s safety position. FDA’s compounding safety review of BPC-157 found no or only limited safety information for the proposed routes.[7]
What FDA has said and done
- On supplements generally, FDA states that it does not approve dietary supplements and that manufacturers are responsible for their safety.[5]
- On BPC-157, FDA’s page on bulk substances that may present significant safety risks in compounding still carries its safety summary, citing possible immunogenicity and peptide-impurity concerns. As of April 2026, BPC-157 sits in that page’s table of nominations withdrawn by the nominators rather than in Category 2.[7] Our FDA peptide ban 2026 guide tracks that.
- On marketing claims, FDA and the FTC regulate supplement labeling and advertising. Our peptide advertising rules and FDA warning letters on peptides guides cover enforcement.
Practical takeaways
- An oral collagen or protein peptide product can be a lawful supplement.
- A synthetic signaling peptide sold for injection cannot.
- Approved peptide drugs are permanently excluded unless sold as food or supplements first.
- Labels do not decide legal status; ingredients, route and intended use do.
See also GRAS peptides for how food-ingredient status differs from supplement status.
This is general information, not legal advice. Supplement law turns on specific facts, and FDA’s interpretations can change.
